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Genome-wide association studies have implicated the
TERT-CLPTM1L locus at 5p15.33 in susceptibility to a
variety of cancers including pancreas, lung, skin and
glioma, suggesting that TERT may act as a “pan-cancer
susceptibility locus” in a similar manner to the 8q24
region.
We initially identified an association between an intro-
nic TERT SNP rs7726159 and epithelial ovarian cancer
(EOC) risk through an Illumina GoldenGate scan of sin-
gle nucleotide polymorphisms (SNPs) in candidate genes,
with a more pronounced effect in serous cases (Johnatty
et al, PloS Genetics 2010). We employed a fine-mapping
strategy of a 500 kb region of the TERT-CLPTM1L locus
using data from the 1000Genomes and HapMap Projects,
and cases and controls from the Ovarian Cancer Associa-
tion Consortium (OCAC). Using single-marker and step-
wise logistic regression adjusted for age and study, we
analysed 28 SNPs in 2,130 invasive epithelial ovarian can-
cer cases, including 1,076 of serous histology, and 3,975
controls of Caucasian ancestry from nine OCAC studies,
and observed a significant association between serous
cases and a TERT promoter SNP rs2736109 [adj. ORper-
allele 0.86 (0.77-0.96), P = 0.005].
Since much of the genetic architecture is shared
between EOC and breast cancer, we analysed rs2736109
in 4,277 invasive breast cancer cases and 7,000 controls
from the Breast Cancer Association Consortium
(BCAC). Although there was no association with inva-
sive breast cancer risk overall [adj. ORper-allele =0 . 9 5
(0.90 - 1.01) P = 0.10], we found the strongest evidence
of association among ER-negative cases over the age of
50 (n=636) [adj. ORper-allele 0.84 (0.75-0.95), P = 0.005].
To examine the potential functional consequences of
rs2736109 and another promoter SNP, rs2736108, we
generated luciferase reporter constructs comprising 3.7
kb of the TERT promoter containing various combina-
tions of alleles and transfected them into breast and
ovarian cell lines. We observed a decrease in luciferase
expression by the presence of both the A alleles at
rs2736108 and rs2736109, but not when either allele is
present alone. Our analysis of 345 Australian controls
suggests that the A-A haplotype at rs2736108 and
rs2736109 occurs with a frequency of 32%, suggesting
that this relatively common promoter haplotype may
lower the risk of serous epithelial ovarian cancer though
decreasing TERT expression.
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